Emeryville, CA and Columbia, MD | July 24, 2017  — 4D Molecular Therapeutics (4DMT), a leader in adeno-associated virus (AAV) gene therapy vector discovery and product development, and the Foundation Fighting Blindness (FFB), the world’s largest non-governmental source of research funding for

Intravitreal delivery to the retina is critical to Choroideremia treatment Emeryville, CA | December 23, 2016 —  4D Molecular Therapeutics (4DMT), a leader in gene therapy product discovery and development, today announced the enrollment of the first participant in its Choroideremia Natural History

Intravitreal delivery to the retina is critical to Choroideremia treatment Emeryville, CA | February 23, 2016  — 4D Molecular Therapeutics (4DMT), a leader in Adeno-Associated Virus (AAV) gene therapy vector discovery and product development, and the Choroideremia Research Foundation (CRF), a

Leader in proprietary gene therapy vector discovery closes fifth partnership Emeryville, CA, Jan 7, 2016  — 4D Molecular Therapeutics (4DMT), a leader in Adeno-Associated Virus (AAV) gene therapy vector discovery and product development, today announced both an investment by and a collaboration and